Phase III trial of Rapamune versus placebo in primary renal allograft recipients

Saved in:
Bibliographic Details
Published inTransplantation proceedings Vol. 33; no. 3; pp. 2271 - 2272
Main Authors Ponticelli, C, MacDonald, A.S, Rajagopalan, P, Sindhi, R, Mathew, T
Format Journal Article Conference Proceeding
LanguageEnglish
Published New York, NY Elsevier Inc 01.05.2001
Elsevier Science
Subjects
Adolescent
Adrenal Cortex Hormones - therapeutic use
Adult
Aged
Biological and medical sciences
Cadaver
Cyclosporine - therapeutic use
Dose-Response Relationship, Drug
Double-Blind Method
Drug Therapy, Combination
Female
Graft Survival - drug effects
Graft Survival - physiology
Humans
Hypercholesterolemia - epidemiology
Immunomodulators
Immunosuppressive Agents - adverse effects
Immunosuppressive Agents - therapeutic use
Kidney Transplantation - immunology
Kidney Transplantation - mortality
Kidney Transplantation - physiology
Living Donors
Male
Medical sciences
Middle Aged
Opportunistic Infections - epidemiology
Pharmacology. Drug treatments
Placebos
Postoperative Complications - epidemiology
Risk Factors
Sirolimus - adverse effects
Sirolimus - therapeutic use
Survival Rate
Thrombocytopenia - chemically induced
Time Factors
Tissue Donors
Transplantation, Homologous
Triglycerides - blood
Phase III trial
Sirolimus
Treatment efficiency
Controlled therapeutic trial
Transplantation
Homotransplantation
Macrolide
Kidney
Prevention
Rejection
Chemotherapy
Treatment
Urinary system
Surgery
Double blind study
Graft
Comparative study
Online AccessGet full text

Cover

More Information
ISSN:0041-1345
1873-2623
DOI:10.1016/S0041-1345(01)01987-X